Biotechnological drugs have also proved to be effective in AOSD (Ruscitti et al., 2017), and indeed many compelling pathogenetic data (Pascual et al., 2005; Church et al., 2008; Mellins et al., 2011; Gerfaud-Valentin et al., 2014) consider interleukin (IL)-1 as the main orchestrating cytokine in sJIA and AOSD pathways, providing the biologic rationale of IL-1 inhibition in these two entities, which are now deemed autoinflammatory in nature (Hayem, 2009; Rossi-Semerano and Koné-Paut, 2012). The gene discussed is IL1A; the disease is adult-onset Still disease.